Evotec SE (NASDAQ:EVO - Free Report) - Analysts at HC Wainwright reduced their FY2027 earnings per share (EPS) estimates for Evotec in a research report issued to clients and investors on Monday, April 21st. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of $0.42 per share for the year, down from their previous forecast of $0.47. The consensus estimate for Evotec's current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Evotec's FY2028 earnings at $0.57 EPS and FY2029 earnings at $0.70 EPS.
Separately, Deutsche Bank Aktiengesellschaft raised shares of Evotec from a "sell" rating to a "hold" rating in a report on Thursday.
View Our Latest Stock Report on Evotec
Evotec Trading Up 0.2 %
Shares of EVO stock traded up $0.01 during mid-day trading on Tuesday, hitting $4.22. 21,000 shares of the stock traded hands, compared to its average volume of 135,218. The stock's fifty day moving average is $3.64 and its two-hundred day moving average is $4.09. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.99 and a current ratio of 2.09. Evotec has a 52-week low of $2.84 and a 52-week high of $5.68.
Institutional Investors Weigh In On Evotec
A number of large investors have recently modified their holdings of the business. BNP Paribas Financial Markets acquired a new stake in Evotec in the 4th quarter worth approximately $27,000. Bank of America Corp DE raised its holdings in shares of Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company's stock worth $53,000 after buying an additional 9,289 shares during the last quarter. CSS LLC IL purchased a new position in shares of Evotec in the fourth quarter worth $50,000. DCF Advisers LLC lifted its stake in shares of Evotec by 5.9% during the fourth quarter. DCF Advisers LLC now owns 229,871 shares of the company's stock worth $956,000 after buying an additional 12,816 shares during the period. Finally, Lighthouse Investment Partners LLC purchased a new stake in shares of Evotec during the fourth quarter valued at $166,000. Hedge funds and other institutional investors own 5.81% of the company's stock.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Further Reading
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
